European Journal of Haematology

Final results from a large, non-interventional, phase 4 study of ruxolitinib for the treatment of myelofibrosis in clinical routine

American Journal of Hematology

Impact of donor type on outcomes after allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT

Journal of Hematology

Efficacy and safety of momelotinib in myelofibrosis: A systematic review and meta-analysis with a focus on anemia outcomes

Transplantation and Cellular Therapy

Risk stratification using DIPSS and splenomegaly in myelofibrosis treated with pre-transplant JAK inhibitors

International Journal of Hematology

Efficacy and safety of momelotinib in Janus kinase inhibitor experienced Asian patients with myelofibrosis and anemia

Clinical Lymphoma, Myeloma & Leukemia

Real-world evidence on outcomes and safety of ropeginterferon alfa-2b in patients with myeloproliferative neoplasms: A retrospective cohort study

Journal of Inflammation Research

Prognostic implications of red blood cell distribution width to albumin ratio in myelofibrosis: A 10 year multicenter and retrospective study

Acta Haematologica

Impact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP studyImpact of early-onset or worsening anemia in patients with myelofibrosis treated with ruxolitinib: A post hoc analysis of the JUMP study

Indian Journal of Hematology and Blood Transfusion

Renal impairment in myeloproliferative neoplasms: An under-reported complication

European Journal of Haematology

Time without transfusion reliance (TWiTR): Integrating survival quality into myelofibrosis treatment strategies based on the phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials